SCHEMBL1336092

SCHEMBL1336092

Clc1cccc(-n2ccnn2)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 13/20 1.00
KEAP1 Q14145 1/20 0.64
IDO1 P14902 1/20 0.50
FLT3 P36888 2/20 0.49
GSK3B P49841 1/20 0.49
POLB P06746 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14961974 0.86 NOTUM (0.75) NOTUMKEAP1
SCHEMBL10983173 0.80 NOTUM (0.68) NOTUMKEAP1
SCHEMBL2733044 0.78 NOTUM (0.64) NOTUMKEAP1
SCHEMBL21776982 0.78 KEAP1 (1.00) NOTUMKEAP1
SCHEMBL2627224 0.78 NOTUM (0.64) NOTUMKEAP1
SCHEMBL670667 0.78 NOTUM (0.65) NOTUMKEAP1
SCHEMBL11410355 0.78 NOTUM (0.64) NOTUMKEAP1
SCHEMBL3156314 0.78 NOTUM (0.64) NOTUMKEAP1
SCHEMBL30731222 0.78 NOTUM (0.64) NOTUMKEAP1
SCHEMBL4536618 0.77 NOTUM (0.63) NOTUMKEAP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-114907323-B Quinoxalinone compounds, preparation method and application thereof 内蒙古民族大学 2023-08-15 CN disclosed
US-11634391-B2 Compounds which are inhibitors of Notum UCL BUSINESS LTD (GB) 2023-04-25 US disclosed
CN-114907323-A Quinoxalinone compounds and preparation method and application thereof 内蒙古民族大学 2022-08-16 CN disclosed
EP-3843844-A1 COMPOUNDS UCL Business Ltd (GB) 2021-07-07 EP disclosed
US-20210171475-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2021-06-10 US disclosed
WO-2020043866-A1 COMPOUNDS UCL BUSINESS LTD (GB) 2020-03-05 WO disclosed
US-9550757-B2 Nuclear transport modulators and uses thereof Karyopharm Therapeutics Inc. (US) 2017-01-24 US disclosed
EP-2542089-B1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF KARYOPHARM THERAPEUTICS INC (US) 2017-01-18 EP disclosed
US-20140155370-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF Karyopharm Therapeutics Inc. 2014-06-05 US disclosed
US-8513230-B2 Nuclear transport modulators and uses thereof KARYOPHARM THERAPEUTICS, INC. (US) 2013-08-20 US disclosed
EP-2542089-A1 NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF Karyopharm Therapeutics, Inc. (US) 2013-01-09 EP disclosed
US-20110275607-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF KARYOPHARM THERAPEUTICS, INC. (US) 2011-11-10 US disclosed
WO-2011109799-A1 NUCLEAR TRANSPORT MODULATIORS AND USES THEREOF KARYOPHARM THERAPEUTICS, INC. (US) 2011-09-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11634391-B2 Compounds which are inhibitors of Notum NOTUM, GOT2, GOT1 NOTUM 1/4885KEAP1 764/4885IDO1 2743/4885
US-20140155370-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, NXF1, XPOT NOTUM 4789/4885KEAP1 71/4885IDO1 2852/4885
US-20110275607-A1 NUCLEAR TRANSPORT MODULATORS AND USES THEREOF XPO1, NXF1, XPOT NOTUM 4789/4885KEAP1 71/4885IDO1 2852/4885
US-20210171475-A1 COMPOUNDS GOT2, GOT1, OAT NOTUM 5/4885KEAP1 411/4885IDO1 4116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.